TIDMN4P
RNS Number : 6256Z
N4 Pharma PLC
21 May 2019
21 May 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Board Changes
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for vaccines and
cancer treatments, is pleased to announce the appointment of Dr
John Chiplin as Non-Executive Chairman of the Company, and the
appointment of Dr Chris Britten as a Non-Executive Director of the
Company (the "Appointments"). In addition, Paul Titley has decided
to step down from the board for personal reasons and Dr David
Templeton, formerly Chairman, will now serve as a part-time
Executive Director in order to manage the technical aspects of the
Company's Nuvec(R) programme. All board changes are effective
immediately. The Board would like to take this opportunity to thank
Paul Titley for his valuable contribution to the Company over the
last two years.
Dr John Chiplin has significant operational, investment and
transaction experience in the life science and technology
industries. Between 1995 and 2014, Dr Chiplin served as CEO of
three leading publicly listed software, biotechnology and cancer
immunotherapy companies in the US. Based in London, Dr Chiplin's
current board roles include Adalta, Cynata, Regeneus and Scancell
Holdings plc (AIM: SCLP). He is also Managing Director of Newstar
Ventures Ltd, an international private equity firm focused on
emerging companies.
Dr Chris Britten is an experienced pharmaceutical executive and
is currently Head of M&A at Neuraxpharm, a privately-owned
European CNS specialty pharmaceutical company. He has over 20
years' experience in R&D, corporate development and investment
banking. Previous roles include Global Head of M&A at Sandoz
(Munich), Managing Director at Torreya Partners (London), Head of
Business Development at Sanofi Pasteur MSD (Lyon) and Director,
Life Sciences at Deloitte Corporate Finance (London). Chris also
spent many years at GSK in both drug discovery and corporate
development.
Option Grant
In conjunction with the Appointments, Dr John Chiplin and Dr
Chris Britten have each been granted 717,143 options over new
ordinary shares in the Company ("Options"). The Options represent
approximately 1.41 per cent. of the Company's existing issued share
capital, and have been issued pursuant to the Company's Unapproved
Share Option Scheme. The Options have an exercise price of 3.55
pence per Option, which was the closing mid-market price of an
Ordinary Share in the Company on 20 May 2019, being the day prior
to the grant. The Options can be exercised from three years from
the grant date and up to the tenth anniversary of the grant date,
provided that the individual remains an employee of the
Company.
The FCA notifications in respect of the Option grants, made in
accordance with the requirements of the EU Market Abuse Regulation,
are appended below.
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"I am delighted that John and Chris have agreed to join our
board. Their considerable experience will strengthen our team and
will provide a strong boost to our commercialisation plans for
Nuvec(R).
"Equally, I am delighted that David is now able to take an
executive role to oversee all technical aspects of our Nuvec(R)
programme and any other assets we may bring into the Company's
portfolio.
"I would also like to thank Paul for all the time and support he
has provided me personally to help grow the Company from its early
origins."
AIM Rules Disclosures
Dr John Chiplin, aged 60, is or has been during the last five
years, a director or partner of the following companies and
partnerships:
Current directorships/partnerships Past directorships/partnerships
Scancell Holdings plc Sienna Cancer Diagnostics Limited
Coma Research Institute Polynoma LLC
Regeneus Ltd Benitec Biopharma Limited
Scancell Limited Prophecy Inc.
Cynata Therapeutics Limited Endava LLC
Newstar Ventures Pty Ltd
AdAlta Limited
Batu Biologics Inc.
ScienceMedia Inc.
Dr Christopher Jonathan Britten, aged 51, is or has been during
the last five years, a director or partner of the following
companies and partnerships:
Current directorships/partnerships Past directorships/partnerships
None Phico Therapeutics Ltd
There is no further information required to be disclosed
pursuant to Schedule 2(g) of the AIM Rules.
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr John Chiplin
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name N4 Pharma plc
-------------------------- ------------------------------------------
b) LEI 213800I841D2RKMFK955
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the Options over ordinary shares of
financial instrument, 0.4p each in N4 Pharma plc
type of instrument
Identification code Identification code (ISIN) for N4
Pharma plc ordinary shares: GB00BYQCDH57
-------------------------- ------------------------------------------
b) Nature of the transaction Grant of Options
-------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of 3.55p 717,143
----------
-------------------------- ------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 21 May 2019
-------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Chris Britten
-------------------------- ------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- ------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------
a) Name N4 Pharma plc
-------------------------- ------------------------------------------
b) LEI 213800I841D2RKMFK955
-------------------------- ------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------
a) Description of the Options over ordinary shares of 0.4p
financial instrument, each in N4 Pharma plc
type of instrument
Identification code Identification code (ISIN) for N4 Pharma
plc ordinary shares: GB00BYQCDH57
-------------------------- ------------------------------------------
b) Nature of the transaction Grant of Options
-------------------------- ------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise price
of 3.55p 717,143
----------
-------------------------- ------------------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- ------------------------------------------
e) Date of the transaction 21 May 2019
-------------------------- ------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- ------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOADGGDUIUDBGCG
(END) Dow Jones Newswires
May 21, 2019 02:02 ET (06:02 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024